Pipeline
Transforming treatment of chronic conditions
Innovative Therapeutics Pipeline
At Chariot Biosciences, we are dedicated to developing groundbreaking therapies that address critical healthcare needs. Our pipeline focuses on innovative solutions that transform treatment paradigms for rare diseases and chronic conditions.
Enzyme Replacement Therapy for Gaucher Disease
Our lead program targets enzyme replacement therapy (ERT) for Gaucher disease, a rare orphan indication. The standard of care (SOC) involves frequent injections, often costing over $300,000 per year. With a single annual Simmbion implantation, we aim to revolutionize this therapy and streamline the treatment process. As a rare disease, Gaucher disease allows for expedited FDA regulatory pathways, enhancing our ability to bring this innovative solution to patients.
Expanding Our Pipeline
Chariot Biosciences is committed to extending its drug development pipeline with additional Simmbion constructs. We are actively working on therapies targeting diabesity (diabetes and obesity) and cancer, ensuring that we address some of the most pressing health challenges facing patients today.
Let's create a healthier future.
Together.
We’re excited to connect with those who share our passion for innovative healthcare solutions. Whether you have a question or want to learn more about Chariot Biosciences, we’d love to hear from you!
Get in Touch